Targeting the interaction between PKC isoforms and their anchoring proteins can specifically regulate kinase activity. eV1-2 and pseudoeRACK peptides, derived from the PKCe C2 domain, modulate its association with receptor for activated C-kinase 2 (RACK2) and thus its function. Details of these interactions remain obscure, and we therefore investigated binding of these peptides using biophysical techniques. Surface plasmon resonance (SPR) indicated that the inhibitory eV1-2 peptide bound to RACK2, and inhibited PKCe binding as expected. In contrast, SPR and NMR demonstrated that the activating pseudoeRACK peptide and related sequences did not bind to PKCe, indicating that their mechanisms of action do not involve binding to the kinase as previously proposed. Our results clarify which interactions could be targeted in developing new therapeutics that inhibit PKCe-RACK2 interaction.
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Keywords: C2 domain; peptides; protein kinase C; RACK2; saturation transfer difference NMR; surface plasmon resonance Isoforms of the lipid-activated protein kinase C (PKC) family play wide-ranging roles in the regulation of cellular processes, including survival, growth, proliferation, differentiation, metabolism and apoptosis [1, 2] . Aberrant activity of these enzymes has also been implicated in disease states such as cancer, immune disorders and diabetes [3] , and specific isoforms are potential targets for treatment [4] . Much attention has therefore been focused on understanding the regulatory mechanisms controlling particular PKC activities. While activation by the second messengers diacylglycerol (DAG) and calcium is important, targeting of the kinases to diverse cellular locations by scaffolding proteins has also emerged as a determinant of substrate protein phosphorylation [5] and can serve as a focus for the development of therapeutic agents [6, 7] .
PKCs can be divided into three groups, based on their structure and sensitivity to certain activators [8] . The first group to be characterised was the conventional or classical PKCs, comprising PKCa, PKCb and PKCc, which are sensitive to increases in both intracellular DAG and calcium by virtue of their C1 Abbreviations DAG, diacylglycerol; NMR, nuclear magnetic resonance; NTA, nitrilotriacetic acid; PKC, protein kinase C; RACK2, receptor for activated Ckinase 2; SPR, surface plasmon resonance; STD, saturation transfer difference. and C2 domains, respectively. The PKC isoforms PKCd, PKCe, PKCg and PKCh are calcium-insensitive but DAG-dependent. The modified C2 domains of these kinases have low affinity for calcium but are involved in diverse protein-protein interactions. Finally, the atypical PKCs, PKCf and PKCι are DAG-independent and may be constitutively active and directed solely by protein interactions [9] .
Inhibition of PKC activity can be achieved using catalytic site inhibitors, but this results in poor isoform selectivity owing to the conserved nature of the PKC C3 and C4 domains involved in ATP and substrate binding. For example, the widely used PKC inhibitor bisindolylmaleimide I (G€ o 6850, GF-109203X) inhibits all conventional PKCs with a similar IC 50 of approximately 20 nM, while a related compound inhibits both conventional and novel PKCs with a similar affinity. On the other hand, targeting the more isoform-specific interactions of PKCs with scaffolding proteins, which bring kinase activity into close proximity with particular substrates, appears to be more successful for selective inhibition and delineation of the roles of different members of the kinase family. Distinct groups of PKC binding proteins have been described, the best characterised being the A-kinase anchor proteins that bind combinations of kinases, phosphatases and substrates [10] , and the receptors for activated C-kinase (RACKs) that target specific PKC isoforms to distinct intracellular locations together with particular substrates [11] . The PKCb RACK (RACK1) appears to bring together PKCb and PLCc, ras-GAP, Src tyrosine kinase or integrin b subunit, while the PKCe RACK (RACK2, also known as COPB2) [12] is a member of the COPI coatomer complex and also binds to other coatomer proteins and the small ras-like GTPase, ARF [13, 14] .
PKCe is a ubiquitously expressed novel PKC that plays roles in diverse processes such as nociceptor function, GABA A receptor regulation and macrophage activation, and has also been implicated in transformed cell cytokinesis, cardiac hypertrophy and type 2 diabetes. The N-terminal C2 domain of PKCe (residues 1-148), initially referred to as the V1 variable region because of its limited homology with the classical PKC C2 domain and lack of calcium-coordinating residues, contains a putative binding site for RACK2 (Fig. 1A) [12] . A peptide (eV1-2) derived from this sequence (PKCe [14] [15] [16] [17] [18] [19] [20] [21] , EAVSLKPT) [15] has been widely used as a PKCe antagonist by inhibiting PKCe binding to RACK2, thus implicating PKCe in several cellular processes such as ischaemia preconditioning in cardiomyocytes and insulin secretion in pancreatic b-cells [16] [17] [18] .
The inactive conformation of PKC is stabilised by intramolecular interactions, including the interaction of the C-terminal catalytic site with a pseudosubstrate region (Fig. 1B) [19] . It has also been proposed that the region in PKCe comprising residues 85-92 (HDA-PIGYD), which is partly homologous to RACK2 residues 285-292 (NNVALGYD), mimics RACK2. This is therefore called the pseudoeRACK region. As shown in Model 1 in Fig. 1B , the pseudoeRACK region was suggested to further stabilise the inactive kinase through an intramolecular interaction with the eV1-2 region [20] . A peptide derived from this pseudoeRACK region (weRACK peptide) is thought to prevent this intramolecular stabilisation by binding to PKCe and has been used as a PKCe agonist (Fig. 1C ) [20, 21] . It was initially proposed that this intramolecular interaction occurred within the C2 domain of PKCe (Fig. 1B) [20] . However, the subsequently reported structure of this domain suggests that this is unlikely [22] , and other regions are likely to be involved, such as the C-terminal V5 region [23, 24] . Model 2 in Fig. 1B shows an alternative mode by which intramolecular interactions between the pseudoeRACK region and the C-terminal V5 region may stabilise the inactive conformation of PKCe [23] . In this case, the weRACK peptide may displace the pseudoeRACK region from the V5 region to activate the kinase.
The PKCe regions involved in RACK2 and pseudoeRACK interactions represent targets for the design of small molecule inhibitors and activators of PKCe with therapeutic potential for pain, cancer and diabetes, but are not well-defined. Here, we examine the binding of PKCe to RACK2 using biophysical techniques in order to clarify the actions of the modulatory peptides.
Materials and methods

Peptides
Peptides were obtained from Purar Chemicals (Doncaster, VIC, Australia), and their identity and purity (> 90%) were verified by mass spectrometry and HPLC, respectively. The sequences were as follows: eV1-2, EAVSLKPT (PKCe [14] [15] [16] [17] [18] [19] [20] [21] ); weRACK, HDAPIGYD (PKCe 85-92 ); N-weRACK, HNA-PIGYD and the homologous sequence in RACK2, NNVAL-GYD (RACK2 285-292 ). All peptides were N-acetylated and C-amidated.
Surface Plasmon Resonance (SPR)
Surface plasmon resonance measurements were performed on a Biacore T200 instrument at 25°C. His6-tagged PKCe or its C2 domain was diluted to 1 lgÁmL À1 in running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 50 lM EDTA, 0.05% v/v Tween20) and captured onto a NiHC200M sensor chip coated with an nitrilotriacetic acid (NTA)-derivatised hydrogel matrix, prepared according to the manufacturer's instructions (XanTec Bioanalytics, Germany). Recombinant RACK2 was injected over the immobilised surface at a rate of 60 lLÁmin À1 for 5 min in running buffer at concentrations ranging from 12.5 to 200 nM, followed by dissociation for 10 min. NTA captured His6-tagged PKCe or PKCe C2 was evaluated by SPR. Serially diluted peptides (12.5-0.78 lM) were injected over the immobilised proteins at a rate of 60 lLÁmin À1 for 3 min followed by dissociation for 5 min.
The expected maximum binding responses (expected R max ) for these peptides were estimated by scaling the maximum binding response observed (observed R max ) for RACK2 to the molecular weight of these peptides [25] .
In separate experiments, RACK2 was amine-coupled to the surface of a CM5 chip, and PKCe and eV1-2 peptide were injected at concentrations ranging from 12.5 to 200 nM and 125 nM to 8 lM, respectively, at a rate of 60 lLÁmin À1 for 2 min followed by dissociation for 5 min.
The reference flow cell sensorgrams were subtracted from the ligand flow cell sensorgrams for all analyses. The binding responses at the steady-state region of the sensorgrams were plotted as a function of the peptide concentration to obtain the binding curves. These curves were fitted to a steady-state model to derive the apparent equilibrium dissociation constant (K D ). GraphPad Prism software (version 6.0; GraphPad software, Inc.) was used for the analysis of steady-state SPR data. The binding affinity of eV1-2 peptide for RACK2 was also measured by an SPR solution competition assay. A standard calibration curve was established by flowing RACK2 (200-3.1 nM) over PKCe C2 domain immobilised on a NiHC200M NTA chip. Varying concentrations (14 nM-10 lM) of eV1-2 peptide in the presence of 50 nM RACK2 were then flowed over immobilised PKCe C2 domain to measure the competition. The percentage of maximum response (for 50 nM RACK2) was plotted against the concentration of the peptide competitor to derive an apparent IC 50 .
NMR spectroscopy
All NMR experiments were performed on a Bruker Avance 600 MHz spectrometer at 10°C. In the saturation transfer difference (STD) NMR experiments, saturation was achieved with a train of 50 ms Gaussian pulses at a field strength of 100 Hz for 3 s [26] . The irradiation frequency of the saturation pulse train was changed after every scan (onand off-resonance frequencies were 60 and À20 000 Hz, respectively). Samples were prepared for STD experiments by mixing PKCe or PKCe C2 domain with weRACK, eV1-2, N-weRACK or RACK2 285-292 peptides in 10 mM phosphate buffer pH 6.5 containing 50 mM sodium chloride and 10% 2 H 2 O. The final concentrations of PKCe and its C2 domain were 3.5 and 5 lM, respectively. The final concentrations of the peptides were 100 lM. A difference spectrum of the off-resonance and on-resonance spectrum yields signals appearing due to saturation transfer from the protein to the ligand. STD spectra were acquired with 128 scans with 8 dummy scans using a sweep width of 13 p.p.m. An exponential line broadening function of 3 Hz was applied prior to Fourier transformation.
Results
The interaction of PKCe with RACK2 is mediated by its C2 domain
To investigate the binding of PKCe to RACK2, fulllength proteins and the PKCe C2 domain were expressed in insect cells or Escherichia coli (E. coli) and purified by affinity chromatography using 6-His and biotin tags, respectively (Fig. S1A) . Full-length PKCe exhibited kinase activity towards peptide and protein substrates (Fig. S1B,C) as reported previously [27] . We first confirmed that the recombinant forms of these proteins interacted in vitro using SPR. RACK2 was able to bind PKCe immobilised on an NTA chip ( Fig. 2A) , giving an affinity of 9 nM. RACK2-bound PKCe with a slow on-rate and the complex had a slow dissociation rate (Table 1) . In a separate experiment, RACK2 was amine-coupled to the surface of a CM5 chip and binding of PKCe to immobilised RACK2 was monitored (Fig. S2) . The binding affinities obtained under these conditions were similar to those determined with immobilised PKCe. SPR also demonstrated that the PKCe C2 domain alone could bind RACK2, with an affinity of 12.5 nM (Fig. 2B) , indicating its importance in the interaction.
The C2 domain-derived eV1-2 peptide also binds RACK2
While the eV1-2 peptide inhibits PKCe intracellular translocation and function [15] , its direct binding to RACK2 has not been demonstrated. Here, we measured binding of the eV1-2 peptide to RACK2 by SPR (Fig. 3A) . This demonstrated that eV1-2 peptide bound RACK2 in a dose-dependent manner with an (Table 1) . Furthermore, dose-dependent inhibition of PKCe C2 domain-RACK2 binding was also observed using the eV1-2 peptide, giving an apparent IC 50 of 3.3 lM (Fig. 3C) . Collectively, these results indicate that the eV1-2 site on the C2 domain of PKCe is the likely site of interaction with RACK2. As expected, the eV1-2 peptide did not directly affect PKCe kinase activity in vitro (Fig. S3) , consistent with a mechanism of action involving the inhibition of PKCe binding to RACK2 in intact cells.
The pseudoeRACK and eV1-2 sites are not involved in intramolecular interactions
The weRACK peptide from the C2 domain of PKCe is thought to act as an agonist and promote the binding of RACK2 to PKCe in a two-step mechanism [21] ( Fig. 1C) . weRACK peptide has been shown to promote the translocation of PKCe to various subcellular compartments in several model systems, but the molecular basis of its action is unknown. To further investigate these interactions, we first tested the direct binding of the weRACK peptide to the C2 domain of PKCe using STD NMR. In this experiment, the resonances of the C2 domain protein were selectively saturated and the saturation transfer effect on the resonance intensities of the free peptide was monitored. The STD difference spectrum of the weRACK peptide in the presence of PKCe C2 domain did not show any detectable STD signals, indicating that this peptide does not bind to the C2 domain of PKCe (Fig. 4A) . The absence of an STD signal could also be due to slow dissociation of the peptide, in which case the saturation transfer to the peptide in solution would not be efficient and there would be no STD built up. We therefore used SPR to further assess weRACK peptide binding to PKCe C2 domain immobilised on an NTA chip. Using the RACK2 binding response on this immobilised surface as a reference, the theoretically calculated maximum response (R max ) for weR-ACK peptide was 6 RU, but the measured signal response was only 0.5 RU. The low signal response observed for weRACK peptide and the absence of dose-dependent binding confirmed the lack of binding of weRACK peptide to the C2 domain (Fig. 4B ).
Other sites on PKCe have been implicated in RACK2 binding, including the V5 region (Fig. 1B,  Model 2 ) [24] . Having established that the weRACK peptide did not bind to the C2 domain of PKCe, we investigated whether this peptide interacted with any other regions of PKCe. However, no detectable interaction between the weRACK peptide and full-length PKCe was observed by SPR (Fig. 4C) , and the peptide did not directly affect PKCe kinase activity in vitro (Fig. S3) . In addition, the eV1-2 peptide was also found not to bind to full-length PKCe (Fig. 4D,E) or its C2 domain (Fig. S4) , suggesting that the eV1-2 site, although involved in RACK2 binding, is not involved in intramolecular interactions with other regions of PKCe. Furthermore, from the crystal structure of the C2 domain, it appears unlikely that the eV1-2 site could make direct contacts with the pseudoeRACK site (Fig. 4F) , except via self-association. To further investigate the interactions mediated by these regions, we investigated the self-association of the C2 domain of PKCe using SPR, but no detectable interaction was observed (Fig. S5A) . In addition, the C2 domain of PKCe was found to be predominantly monomeric in solution as assessed by size-exclusion chromatography (Fig. S5B) . A small proportion of the protein was found form disulfide-linked dimers in solution, but such dimers are unlikely to be physiologically relevant in the reducing environment of the cytoplasm.
Peptides derived from RACK2 do not interact with PKCe
RACK proteins contain short sequences of homology to their cognate PKC isoforms. The RACK2 sequence NNVALGYD (RACK2 [285] [286] [287] [288] [289] [290] [291] [292] ) is partly homologous with the pseudoeRACK sequence HDAPIGYD in the C2 domain of PKCe and the two sites have been proposed to compete for the same RACK2-binding site in PKCe [20] . We used STD NMR and SPR to evaluate binding of RACK2 [285] [286] [287] [288] [289] [290] [291] [292] to PKCe. This peptide showed no detectable binding to PKCe in STD NMR assays (Fig. 5A) suggesting that this region of RACK2 is unlikely to be the PKCe binding site. This is further supported by the lack of dose-dependent binding as assessed by SPR (Fig. 5B and Fig. S6 ). Furthermore, on mapping this peptide onto the structure of RACK2, it was found that NNVALGYD sequence corresponds to a buried b-strand in the b-propeller domain of RACK2 that is unlikely to form the PKCe interaction interface on RACK2 (Fig 5C) .
A previous study reported the design of a selective antagonist of PKCe, N-weRACK, through substitution of Asp in the weRACK peptide with Asn [28] . NweRACK has been shown to inhibit translocation of PKCe and is thought to mimic RACK2. We used STD NMR and SPR to assess the direct binding of NweRACK to both the C2 domain and full-length PKCe. Similar to the results for the weRACK peptide, we observed no detectable binding of N-weRACK to PKCe or its C2 domain (Fig. S7) . 
The C2 domain interacts with other regions of PKCe
While our results do not support the interaction of the pseudoeRACK site with the eV1-2 site in the C2 domain or any other region of PKCe, they do not exclude other intramolecular interactions involving the C2 domain that could stabilise particular PKCe conformations. We therefore examined the interaction between the C2 domain and full-length PKCe by SPR. The full-length kinase bound the immobilised C2 domain in a dose-dependent manner. The data, though not amenable to quantitative analysis owing to the poor fit of the kinetics data, suggest an apparent K D less than 1.1 lM (Fig. 6 ). These data support the existence of eV1-2-and pseudoRACK-independent interaction sites on PKCe.
Discussion
PKC isoforms are key signalling enzymes [1, 2] and have been implicated in several disease states [3, 4] . Many studies have therefore focussed on their intracellular roles and also mechanisms by which they are regulated. Isoform-specific functions have frequently been deduced from the effects of peptides designed to act either as inhibitors or allosteric activators. While such peptides can serve as starting points for drug discovery [7] , quantitative data regarding their direct binding to the kinases or their binding partners are lacking. Here, we have characterised the interactions of widely used PKCe modulatory peptides by SPR and NMR. While the inhibitory eV1-2 peptide bound to RACK2 and inhibited PKCe binding as expected, the activating eRACK peptides did not bind to any region of PKCe, contrary to the proposed mechanism of allosteric activation [20] .
The affinities we observed for the RACK2 interactions with full-length PKCe and its C2 domain are similar to those reported using other methods [12] , confirming the integrity of the protein preparations employed here. Together with the demonstration that the eV1-2 peptide bound to RACK2 and inhibited the association of the C2 domain, with an IC 50 similar to that previously reported for full-length PKCe [7] , these findings validate our approach and underscore its utility in the investigation of modulatory peptides.
The weRACK peptide has been widely used as a PKCe agonist in intact cells and tissues [29] [30] [31] [32] [33] . However, this peptide and its related sequences N-weR-ACK and NNVALGYD did not bind to either the C2 domain or full-length PKCe in our hands. This was unexpected because the weRACK peptide has been proposed to induce a conformational change in the kinase by relieving autoinhibition at the eV1-2 site or the C-terminal V5 region (Fig. 1B,C) [20, 23, 24] . In addition, the eV1-2 peptide did not bind directly to the PKCe C2 domain or to full-length PKCe. While our peptide binding data alone do not rule out the involvement of the pseudoeRACK or eV1-2 sites in intramolecular interactions of intact PKCe, when taken together with the structural features of the C2 domain and RACK2, they argue against a putative interaction between the pseudoeRACK site and either the eV1-2 site or the V5 region. We do not rule out other intra-or intermolecular interactions [24, 34, 35] , because we did observe that the entire C2 domain could bind to full-length PKCe (Fig. 6) .
Elucidation of the mechanism of action of weRACK peptides therefore requires further investigation, and we suggest that the cellular effects obtained using these reagents should be interpreted with caution. This is also highlighted by the fact that, while several peptide studies have suggested opposing roles for PKCe and PKCd in cardiomyocytes, these have not been confirmed using PKC-deficient mice, which in fact indicate redundancy and compensatory functions of these isoforms in the heart (reviewed in [36] ). In contrast, treatment with the eV1-2 peptide was able to recapitulate the effects of PKCe deletion on insulin secretion by mouse pancreatic islets in vivo and ex vivo [18] and on insulin sensitivity in vivo [37] , in agreement with the findings presented here concerning the ability of this peptide to inhibit PKCe binding to RACK2.
In summary, our results confirm the role of the eV1-2 site in the C2 domain of PKCe in direct binding of the kinase to RACK2, and support the use of eV1-2 peptides to inhibit this interaction. However, in contrast to their proposed mechanism of action, we showed that weRACK peptides do not bind PKCe and that the pseudoeRACK site in the PKCe C2 domain is unlikely to be involved in autoinhibitory interactions to maintain the kinase in its inactive state. Effects observed through the use of these peptides may need to be re-evaluated.
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